

**Table S7.** Pathway enrichment analysis of significantly enriched genes obtained from the transcriptomic dataset GDS3027. The top 20 pathways for each database are shown.

| Database | Gene Set Name   | # Genes in Gene Set (K) | Description  | # Genes in Overlap (k) | k/K    | p-value  | FDR q-value |
|----------|---|-------------------------|--|------------------------|--------|----------|-------------|
| Reactome | REACTOME IMMUNE SYSTEM  | 933                     | Genes involved in Immune System  | 190                    | 0.2036 | 2.24E-78 | 1.51E-75    |
| Reactome | REACTOME ADAPTIVE IMMUNE SYSTEM                               | 539                     | Genes involved in Adaptive Immune System                                 | 125                    | 0.2319 | 3.26E-58 | 1.10E-55    |
| Reactome | REACTOME HEMOSTASIS   | 466                     | Genes involved in Hemostasis   | 101                    | 0.2167 | 2.49E-44 | 5.60E-42    |
| Reactome | REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM                  | 270                     | Genes involved in Cytokine Signaling in Immune system                    | 71                     | 0.263  | 2.54E-37 | 3.98E-35    |
| Reactome | REACTOME PLATELET ACTIVATION SIGNALING AND AGGREGATION        | 208                     | Genes involved in Platelet activation, signaling and aggregation         | 63                     | 0.3029 | 2.95E-37 | 3.98E-35    |
| Reactome | REACTOME DEVELOPMENTAL BIOLOGY                                | 396                     | Genes involved in Developmental Biology                                  | 82                     | 0.2071 | 1.14E-34 | 1.28E-32    |
| Reactome | REACTOME AXON GUIDANCE  | 251                     | Genes involved in Axon guidance  | 61                     | 0.243  | 3.58E-30 | 3.45E-28    |
| Reactome | REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION | 251                     | Genes involved in Class I MHC mediated antigen processing & presentation | 59                     | 0.2351 | 2.15E-28 | 1.81E-26    |
| Reactome | REACTOME SIGNALING BY PDGF                                    | 122                     | Genes involved in Signaling by PDGF                                      | 42                     | 0.3443 | 7.96E-28 | 5.96E-26    |
| Reactome | REACTOME METABOLISM OF PROTEINS                               | 518                     | Genes involved in Metabolism of proteins                                 | 82                     | 0.1583 | 3.34E-26 | 2.25E-24    |
| Reactome | REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS                | 478                     | Genes involved in Metabolism of lipids and lipoproteins                  | 78                     | 0.1632 | 7.44E-26 | 4.56E-24    |
| Reactome | REACTOME INTEGRIN CELL SURFACE INTERACTIONS                   | 79                      | Genes involved in Integrin cell surface interactions                     | 32                     | 0.4051 | 4.09E-24 | 2.30E-22    |

|          |  |     |   |    |        |          |          |
|----------|--|-----|---|----|--------|----------|----------|
| Reactome | REACTOME INTERFERON SIGNALING                                  | 159 | Genes involved in Interferon Signaling                                    | 43 | 0.2704 | 1.12E-23 | 5.79E-22 |
| Reactome | REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2+          | 89  | Genes involved in Response to elevated platelet cytosolic Ca2+            | 33 | 0.3708 | 2.32E-23 | 1.12E-21 |
| Reactome | REACTOME METABOLISM OF CARBOHYDRATES                           | 247 | Genes involved in Metabolism of carbohydrates                             | 52 | 0.2105 | 8.00E-23 | 3.59E-21 |
| Reactome | REACTOME ANTIGEN PROCESSING CROSS PRESENTATION                 | 76  | Genes involved in Antigen processing-Cross presentation                   | 28 | 0.3684 | 5.98E-20 | 2.52E-18 |
| Reactome | REACTOME SIGNALLING BY NGF                                     | 217 | Genes involved in Signalling by NGF                                       | 45 | 0.2074 | 1.14E-19 | 4.51E-18 |
| Reactome | REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM | 168 | Genes involved in Fatty acid, triacylglycerol, and ketone body metabolism | 39 | 0.2321 | 4.75E-19 | 1.78E-17 |
| Reactome | REACTOME GLUCOSE METABOLISM                                    | 69  | Genes involved in Glucose metabolism                                      | 26 | 0.3768 | 6.47E-19 | 2.30E-17 |
| Reactome | REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL        | 91  | Genes involved in Cell surface interactions at the vascular wall          | 29 | 0.3187 | 1.34E-18 | 4.51E-17 |
| KEGG     | KEGG FOCAL ADHESION  | 201 | Focal adhesion  | 68 | 0.3383 | 1.23E-43 | 2.29E-41 |
| KEGG     | KEGG REGULATION OF ACTIN CYTOSKELETON                          | 216 | Regulation of actin cytoskeleton  | 56 | 0.2593 | 2.27E-29 | 2.11E-27 |
| KEGG     | KEGG VIRAL MYOCARDITIS   | 73  | Viral myocarditis   | 34 | 0.4658 | 4.99E-28 | 3.09E-26 |
| KEGG     | KEGG PATHWAYS IN CANCER  | 328 | Pathways in cancer  | 66 | 0.2012 | 2.15E-27 | 1.00E-25 |
| KEGG     | KEGG ANTIGEN PROCESSING AND PRESENTATION                       | 89  | Antigen processing and presentation                                       | 36 | 0.4045 | 6.33E-27 | 2.35E-25 |
| KEGG     | KEGG CELL ADHESION MOLECULES CAMS                              | 134 | Cell adhesion molecules (CAMs)  | 41 | 0.306  | 6.33E-25 | 1.96E-23 |
| KEGG     | KEGG ECM-RECEPTOR INTERACTION                                  | 84  | ECM-receptor interaction  | 33 | 0.3929 | 2.60E-24 | 6.91E-23 |

|          |  |     |   |    |        |          |          |
|----------|--|-----|---|----|--------|----------|----------|
| KEGG     | KEGG LEISHMANIA INFECTION                  | 72  | Leishmania infection  | 30 | 0.4167 | 3.94E-23 | 9.17E-22 |
| KEGG     | KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION  | 118 | Leukocyte transendothelial migration  | 37 | 0.3136 | 4.72E-23 | 9.75E-22 |
| KEGG     | KEGG LYSOSOME                              | 121 | Lysosome  | 36 | 0.2975 | 1.34E-21 | 2.49E-20 |
| KEGG     | KEGG MAPK SIGNALING PATHWAY                | 267 | MAPK signaling pathway  | 51 | 0.191  | 1.95E-20 | 3.30E-19 |
| KEGG     | KEGG CHEMOKINE SIGNALING PATHWAY           | 190 | Chemokine signaling pathway   | 43 | 0.2263 | 2.13E-20 | 3.30E-19 |
| KEGG     | KEGG INSULIN SIGNALING PATHWAY             | 137 | Insulin signaling pathway   | 36 | 0.2628 | 1.32E-19 | 1.89E-18 |
| KEGG     | KEGG NEUROTROPHIN SIGNALING PATHWAY        | 126 | Neurotrophin signaling pathway  | 34 | 0.2698 | 5.41E-19 | 7.19E-18 |
| KEGG     | KEGG ALZHEIMERS DISEASE                    | 169 | Alzheimer's disease   | 39 | 0.2308 | 5.93E-19 | 7.35E-18 |
| KEGG     | KEGG SMALL CELL LUNG CANCER                | 84  | Small cell lung cancer  | 27 | 0.3214 | 1.59E-17 | 1.85E-16 |
| KEGG     | KEGG ALLOGRAFT REJECTION                   | 38  | Allograft rejection   | 19 | 0.5    | 5.17E-17 | 5.65E-16 |
| KEGG     | KEGG CALCIUM SIGNALING PATHWAY             | 178 | Calcium signaling pathway   | 37 | 0.2079 | 1.81E-16 | 1.87E-15 |
| KEGG     | KEGG DILATED CARDIOMYOPATHY                | 92  | Dilated cardiomyopathy  | 27 | 0.2935 | 2.15E-16 | 2.10E-15 |
| KEGG     | KEGG GLIOMA                                | 65  | Glioma  | 23 | 0.3538 | 3.44E-16 | 3.20E-15 |
| Hallmark | HALLMARK EPITHELIAL MESENCHYMAL TRANSITION | 200 | Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis. | 82 | 0.41   | 3.34E-60 | 1.67E-58 |
| Hallmark | HALLMARK MYOGENESIS                        | 200 | Genes involved in development of skeletal muscle (myogenesis).                                  | 73 | 0.365  | 1.92E-49 | 4.80E-48 |
| Hallmark | HALLMARK INTERFERON GAMMA RESPONSE         | 200 | Genes up-regulated in response to IFNG [GeneID=3458].   | 61 | 0.305  | 2.60E-36 | 4.34E-35 |

|          |                                    |     |  |    |        |          |          |
|----------|------------------------------------|-----|--|----|--------|----------|----------|
| Hallmark | HALLMARK OXIDATIVE PHOSPHORYLATION | 200 | Genes encoding proteins involved in oxidative phosphorylation.                                 | 58 | 0.29   | 2.95E-33 | 3.69E-32 |
| Hallmark | HALLMARK APICAL JUNCTION           | 200 | Genes encoding components of apical junction complex.  | 56 | 0.28   | 2.84E-31 | 2.84E-30 |
| Hallmark | HALLMARK APOPTOSIS                 | 161 | Genes mediating programmed cell death (apoptosis) by activation of caspases.                   | 50 | 0.3106 | 1.99E-30 | 1.66E-29 |
| Hallmark | HALLMARK COMPLEMENT                | 200 | Genes encoding components of the complement system, which is part of the innate immune system. | 55 | 0.275  | 2.69E-30 | 1.92E-29 |
| Hallmark | HALLMARK ADIPOGENESIS              | 200 | Genes up-regulated during adipocyte differentiation (adipogenesis).                            | 54 | 0.27   | 2.47E-29 | 1.37E-28 |
| Hallmark | HALLMARK ALLOGRAFT REJECTION       | 200 | Genes up-regulated during transplant rejection.  | 54 | 0.27   | 2.47E-29 | 1.37E-28 |
| Hallmark | HALLMARK COAGULATION               | 138 | Genes encoding components of blood coagulation system; also up-regulated in platelets.         | 45 | 0.3261 | 1.50E-28 | 7.49E-28 |
| Hallmark | HALLMARK FATTY ACID METABOLISM     | 158 | Genes encoding proteins involved in metabolism of fatty acids.                                 | 47 | 0.2975 | 9.34E-28 | 4.18E-27 |
| Hallmark | HALLMARK INTERFERON ALPHA RESPONSE | 97  | Genes up-regulated in response to alpha interferon proteins.                                   | 38 | 0.3918 | 1.00E-27 | 4.18E-27 |
| Hallmark | HALLMARK GLYCOLYSIS                | 200 | Genes encoding proteins involved in glycolysis and gluconeogenesis.                            | 48 | 0.24   | 8.73E-24 | 3.36E-23 |
| Hallmark | HALLMARK HYPOXIA                   | 200 | Genes up-regulated in response to low oxygen levels (hypoxia).                                 | 47 | 0.235  | 6.68E-23 | 2.23E-22 |
| Hallmark | HALLMARK IL2 STAT5 SIGNALING       | 200 | Genes up-regulated by STAT5 in response to IL2 stimulation.                                    | 47 | 0.235  | 6.68E-23 | 2.23E-22 |
| Hallmark | HALLMARK KRAS                      | 200 | Genes up-regulated   | 46 | 0.23   | 4.97E-21 | 1.55E-21 |

|          |                                |     |   |    |        |          |          |
|----------|--------------------------------|-----|---|----|--------|----------|----------|
|          | SIGNALING UP                   |     | by KRAS activation.   |    |        | 22       |          |
| Hallmark | HALLMARK INFLAMMATORY RESPONSE | 200 | Genes defining inflammatory response.   | 44 | 0.22   | 2.52E-20 | 7.42E-20 |
| Hallmark | HALLMARK UV RESPONSE DN        | 144 | Genes down-regulated in response to ultraviolet (UV) radiation.                       | 37 | 0.2569 | 9.50E-20 | 2.64E-19 |
| Hallmark | HALLMARK P53 PATHWAY           | 200 | Genes involved in p53 pathways and networks.  | 43 | 0.215  | 1.72E-19 | 4.53E-19 |
| Hallmark | HALLMARK MTORC1 SIGNALING      | 200 | Genes up-regulated through activation of mTORC1 complex.                              | 42 | 0.21   | 1.14E-18 | 2.71E-18 |
| Biocarta | BIOCARTA BIOPEPTIDES PATHWAY   | 45  | Bioactive Peptide Induced Signaling Pathway   | 17 | 0.3778 | 7.14E-13 | 1.55E-10 |
| Biocarta | BIOCARTA FCER1 PATHWAY         | 41  | Fc Epsilon Receptor I Signaling in Mast Cells   | 15 | 0.3659 | 2.78E-11 | 3.02E-09 |
| Biocarta | BIOCARTA HIVNEF PATHWAY        | 58  | HIV-I Nef: negative effector of Fas and TNF   | 17 | 0.2931 | 7.76E-11 | 5.39E-09 |
| Biocarta | BIOCARTA PGC1A PATHWAY         | 26  | Regulation of PGC-1a  | 12 | 0.4615 | 1.04E-10 | 5.39E-09 |
| Biocarta | BIOCARTA HDAC PATHWAY          | 32  | Control of skeletal myogenesis by HDAC and calcium/calmodulin-dependent kinase (CaMK) | 13 | 0.4062 | 1.24E-10 | 5.39E-09 |
| Biocarta | BIOCARTA NFAT PATHWAY          | 56  | NFAT and Hypertrophy of the heart (Transcription in the broken heart)                 | 16 | 0.2857 | 4.26E-10 | 1.54E-08 |
| Biocarta | BIOCARTA EIF4 PATHWAY          | 24  | Regulation of eIF4e and p70 S6 Kinase   | 11 | 0.4583 | 6.99E-10 | 2.17E-08 |
| Biocarta | BIOCARTA BCR PATHWAY           | 37  | BCR Signaling Pathway   | 13 | 0.3514 | 1.06E-09 | 2.86E-08 |
| Biocarta | BIOCARTA MAPK PATHWAY          | 87  | MAPKinase Signaling Pathway   | 19 | 0.2184 | 1.54E-09 | 3.71E-08 |
| Biocarta | BIOCARTA MTOR PATHWAY          | 23  | mTOR Signaling Pathway  | 10 | 0.4348 | 8.00E-09 | 1.74E-07 |
| Biocarta | BIOCARTA CLASSIC PATHWAY       | 14  | Classical Complement Pathway  | 8  | 0.5714 | 1.69E-08 | 3.11E-07 |

|          |                           |    |   |    |        |          |          |
|----------|---------------------------|----|---|----|--------|----------|----------|
| Biocarta | BIOCARTA COMP PATHWAY     | 19 | Complement Pathway  | 9  | 0.4737 | 1.80E-08 | 3.11E-07 |
| Biocarta | BIOCARTA IL2RB PATHWAY    | 38 | IL-2 Receptor Beta Chain in T cell Activation                                     | 12 | 0.3158 | 1.86E-08 | 3.11E-07 |
| Biocarta | BIOCARTA IGF1MTOR PATHWAY | 20 | Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway                     | 9  | 0.45   | 3.16E-08 | 4.90E-07 |
| Biocarta | BIOCARTA CDC42RAC PATHWAY | 16 | Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration   | 8  | 0.5    | 6.74E-08 | 9.75E-07 |
| Biocarta | BIOCARTA AT1R PATHWAY     | 36 | Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling    | 11 | 0.3056 | 1.07E-07 | 1.46E-06 |
| Biocarta | BIOCARTA IGF1R PATHWAY    | 23 | Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation | 9  | 0.3913 | 1.38E-07 | 1.76E-06 |
| Biocarta | BIOCARTA PTEN PATHWAY     | 18 | PTEN dependent cell cycle arrest and apoptosis                                    | 8  | 0.4444 | 2.13E-07 | 2.57E-06 |
| Biocarta | BIOCARTA FMLP PATHWAY     | 39 | fMLP induced chemokine gene expression in HMC-1 cells                             | 11 | 0.2821 | 2.68E-07 | 3.06E-06 |
| Biocarta | BIOCARTA RHO PATHWAY      | 32 | Rho cell motility signaling pathway   | 10 | 0.3125 | 3.23E-07 | 3.51E-06 |